ADVANCING ORFV-BASED VACCINES FOR HUMAN AND ANIMAL HEALTH

ADVANCING ORFV-BASED VACCINES FOR HUMAN AND ANIMAL HEALTH

ADVANCING ORFV-BASED VACCINES FOR HUMAN AND ANIMAL HEALTH

OUR PIPELINE

Prime Vector Technologies is advancing a focused pipeline of ORFV-based vaccines and immunotherapies for human and animal health. Our programs target high-need areas including infectious diseases, veterinary health challenges and therapeutic cancer vaccination.


CANCER

Partnered

(Undisclosed)


Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Partnered (Undisclosed)

Pre-Clinical

Clinical Phase I

Clinical Phase II

Clinical Phase III

INFECTIOUS DISEASES

COVID-19

Prime-2-CoV

Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Pre-Clinical

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Prime-2-CoV vaccine concept
Prime-2-CoV leverages our ORFV platform to deliver both the Spike (S) and Nucleocapsid (N) antigens in a single vector. The multivalent design aims to generate broad and durable immune responses while providing enhanced protection against emerging viral variants.

Prime-2-CoV vaccine concept
Prime-2-CoV leverages our ORFV platform to deliver both the Spike (S) and Nucleocapsid (N) antigens in a single vector. The multivalent design aims to generate broad and durable immune responses while providing enhanced protection against emerging viral variants.

Universal Influenza Vaccine

Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Universal Influenza Vaccine

Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Universal Influenza Vaccine

Pre-Clinical

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Intregrated systemic and mucosal immunity for broad influenza protection

Our multivalent ORFV-based influenza vaccine combines systemic priming with an intranasal booster to induce broad humoral, cellular and mucosal immunity. This integrated strategy is designed to provide durable protection against diverse influenza A virus strains.

Intregrated systemic and mucosal immunity for broad influenza protection

Our multivalent ORFV-based influenza vaccine combines systemic priming with an intranasal booster to induce broad humoral, cellular and mucosal immunity. This integrated strategy is designed to provide durable protection against diverse influenza A virus strains.

Human Metapneumovirus

Pre-Clinical

Clinical Phase I

Clinical Phase II

Clinical Phase III

Human Metapneumovirus


Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Human Meta-pneumovirus


Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Broad protection through mucosal immunity
MucoShield is an intranasal ORFV-based vaccine candidate targeting human metapneumovirus (HMPV). By combining a multivalent antigen design with mucosal immune activation, the platform aims to provide broad and long-lasting protection against multiple HMPV variants.

Broad protection through mucosal immunity
MucoShield is an intranasal ORFV-based vaccine candidate targeting human metapneumovirus (HMPV). By combining a multivalent antigen design with mucosal immune activation, the platform aims to provide broad and long-lasting protection against multiple HMPV variants.

Undisclosed

Pre-Clinical

Clinical Phase I

Clinical Phase II

Clinical Phase III

Undisclosed


Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

PANDEMIC PREPAREDNESS VACCINE PROGRAMM

Various diseases

Pre-Clinical

Clinical Phase I

Clinical Phase II

Clinical Phase III

Various diseases

Pre-Clinical Development

Clinical Phase I

Clinical Phase II

Clinical Phase III

Rapid response for emerging infectious diseases
Our pandemic preparedness platform is designed to accelerate vaccine development for selected emerging and neglected viral diseases. By combining rapid candidate design with scalable manufacturing, the platform aims to strengthen global outbreak preparedness and future pandemic response.

VETERINARY DISEASES

Various Diseases

Early-Phase Development

Late-Phase Development

Various Diseases

Early-Phase Development

Late-Phase Development

A versatile platform for animal health vaccines
Our ORFV-based veterinary vaccine platform is designed for companion and farm animals and enables the development of multivalent vaccine candidates against a wide range of infectious diseases. Its modular design supports cost-efficient manufacturing, scalable production and broad applicability across multiple animal species.